Dexmedetomidine for sedation during endoscopic submucosal dissection of early gastrointestinal lesion

Dexmedetomidine for sedation during endoscopic submucosal dissection of early gastrointestinal lesion - Dexmedetomidine for endoscopic submucosal dissection

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020110

Enrollment

100

Registered

2016-01-01

Start date

2016-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

early esophageal, gastric, duodenal and colorectal cancer or dysplasia

Interventions

Endoscopic submucosal dissection is performed using sedation of dexmedetomidine.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: early esohageal, gastric, duodenal and colorectal cancer or dysplasia. Cases with written and oral informed consent are included.

Exclusion criteria

Exclusion criteria: Cases with severe complications are excluded.

Design outcomes

Primary

Measure	Time frame
Two hours after the treatmentwas finished, patient's quaestionaire about pain, nausea and satisfaction of the sedation is evaluated.	—

Secondary

Measure	Time frame
procedure time, frequency of distarbance by patient's movement, heart rate, blood pressure, SpO2, concious, adverse event, endoscopist, anesthetist and nurse's satisfaction and evaluation using the NASA Task Load Index	—

Countries

Japan

Contacts

Public ContactIppei Matsuzaki

Medical corporation Yamashita Hospital Gastroenterology

imatsu@med.nagoya-u.ac.jp0586-45-4511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026